In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Aclaris Therapeutics, with a price target of $6.00. The company’s shares closed yesterday at $1.81.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, BridgeBio Pharma, and Viking Therapeutics. According to TipRanks, Amin has an average return of 4.2% and a 46.37% success rate on recommended stocks.
Currently, the analyst consensus on Aclaris Therapeutics is a Moderate Buy with an average price target of $7.92.
The company has a one-year high of $5.17 and a one-year low of $1.05. Currently, Aclaris Therapeutics has an average volume of 1.09M.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/Artificial%20intelligence%20and%20machine%20learning%20concept%20-%20by%20amgun%20via%20iStock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/Oracle%20Corp_%20logo%20on%20phone-by%20WonderPix%20via%20Shutterstock.jpg)
